About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Conference & CLE Calendar | Main | QIAGEN And Digene Announce Merger »

June 10, 2007

Agilent Technologies Acquires Stratagene

    By Donald Zuhn --

Agilent_logo Last Thursday, Agilent Technologies Inc. announced that it had completed its $250 million acquisition of Stratagene Corp.  Agilent had announced the agreement to acquire Stratagene, which develops, manufactures, and markets life science research and diagnostic products, two months earlier.

Agilent bills itself as the world's premier measurement company, specializing in gas chromatography and gas chromatography/mass spectrometry devices and liquid chromatography and liquid chromatography/mass spectrometry devices, as well as hardware and software tools for life science analysis including genomics, proteomics, and metabolomics.  According to Agilent's statement, the company pioneered ink-jet in situ synthesis of nucleic acid microarray probes and microfluidic lab-on-a-chip Bioanalyzer and nano LC/MS (Liquid Chromatography/Mass Spectrometry) applications.  Agilent estimates the total addressable life science market to be about $14 billion, and expects the Stratagene_2 acquisition of Stratagene to accelerate its growth in this market.

By acquiring Stratagene, Agilent adds Stratagene's patent portfolio of at least 122 U.S. patents and 87 U.S. published applications to its own extensive patent portfolio.

Agilent also announced that, as part of its deal to acquire Stratagene, $6.6 million in unspecified Stratagene assets had been sold to Decisive Diagnostics, a company formed by former Stratagene chairman, CEO, and founder, Dr. Joseph A. Sorge.

For additional information regarding the acquisition, please see:

Posted at 10:34 PM in Licensing |

Comments

The comments to this entry are closed.

March 2025

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

Categories

Archives

More...